In Reply: The disease that we reported (1) was encephalomyelitis induced by a human herpesvirus 6 (HHV-6) reactivation. Our aim was to emphasize that HHV-6 can cause such a disease, even when the patient is immunocompetent, and to urge physicians to search for it.

Implicating HHV-6 in the pathogenesis of neurologic manifestations in the reported case can be challenged, as suggested by Dr. Soto-Hernandez (2). Polymerase chain reaction (PCR) results must be interpreted cautiously, especially in cases that lack corroborating clinical evidence of infection. In our case, the diagnosis was made initially when HHV-6 was found in the patient’s cerebral spinal fluid (CSF) by using PCR, by the absence of other cause, and by our experience; adult CSF is usually negative for HHV-6 by using PCR. Moreover, in our case, clinical symptoms and HHV-6 in the patient’s CSF evolved in the same way. The neurologic tropism of HHV-6 is well known, and the main manifestation in adults is encephalitis, especially in an immunosuppressed context. Diagnosis is usually based on finding HHV-6 genetic material in the CSF (3,4), which has now replaced staining or in situ hybridization. In the context. Diagnosis is usually based on finding HHV-6 genetic material in the CSF (3,4), which has now replaced staining or in situ hybridization. In our case, the absence of brain tissue did not allow immunohistochemical results for HHV-6 in the CSF by PCR. In our case, the diagnosis was made initially when HHV-6 was found in the patient’s cerebral spinal fluid (CSF) by using PCR, by the absence of other cause, and by our experience; adult CSF is usually negative for HHV-6 by using PCR. Moreover, in our case, clinical symptoms and HHV-6 in the patient’s CSF evolved in the same way. The neurologic tropism of HHV-6 is well known, and the main manifestation in adults is encephalitis, especially in an immunosuppressed context. Diagnosis is usually based on finding HHV-6 genetic material in the CSF (3,4), which has now replaced staining or in situ hybridization. In our case, the absence of brain tissue did not allow immunohistochemical staining or in situ hybridization. In the context of that condition (6). For example, multiple sclerosis developed in 14% of children and 35% of adults with ADEM in the study by Schwarz et al. (7).

Spontaneous improvement of ADEM is regularly reported; however, when treatment is needed, especially during the acute phase, steroid therapy is frequently used. In our case, corticosteroids did not affect the evolution of the patient’s neurologic symptoms. Conversely, the antivirals drugs (cidofovir and ganciclovir) was followed by improved clinical signs and negative results for HHV-6 in the CSF by PCR. Corticosteroids likely influence inflammation associated with ADEM, but if ADEM is the result of a viral infection with persistent viral replication, steroids might be deleterious, allowing an increase in viral replication (8,9).

In conclusion, we think that viruses, particularly HHV-6, should be considered in ADEM, even in immunocompetent patients. In case of a positive result, antiviral treatment must be given, eventually in association with corticosteroids. We cannot recommend using corticosteroids alone because of the risk of spreading the infection.
Vancomycin Heteroresistance in Methicillin-resistant Staphylococcus aureus, Taiwan

To the Editor: In 1997, Hiramatsu and colleagues reported the first clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) showing reduced susceptibility to vancomycin (1). Soon thereafter, vancomycin-intermediate S. aureus (VISA) or heteroresistant VISA was reported to have disseminated in Japanese hospitals (2). In Taiwan, a survey of >5,000 clinical isolates of S. aureus at one tertiary medical center from 1999 to 2001 showed negative results for VISA or vancomycin-resistant S. aureus (VRSA) (3,4). We report the first two isolations of heteroresistant VISA in Taiwan.

In June, 2000, an 89-year-old man (patient A) with a history of cerebrovascular accident underwent ileal resection for ischemic bowel disease, and primary MRSA bacteremia developed during the hospitalization. Vancomycin was given for 14 days, and his fever rapidly abated. In October 2000, a Port-A-Cath (Smiths Industries Medical Systems, Deltec, Inc., St. Paul, MN) was inserted in the left subclavian vein. On June 14, 2001, he had another blood isolate of MRSA during an episode of Enterococcus faecalis bacteremia. Fever resolved after 4 days of intravenous vancomycin treatment (1 g every 12 h), and vancomycin treatment was continued for 21 days. Subsequent culture of blood drawn from the Port-A-Cath and peripheral veins on June 29 and July 6, 2001, did not yield any organism. MRSA bacteremia relapsed in November 2001, and the patient received intravenous teicoplanin treatment (400 mg every 2 days) for 3 weeks, and fever resolved rapidly. Transthoracic echocardiographic tests showed no vegetation on the cardiac valves. The patient was hospitalized again in March 2002 because of relapsing MRSA bacteremia. The Port-A-Cath was removed, and culture of fluid from the indwelling pocket yielded MRSA. Fever and MRSA bacteremia persisted, with 17 sets of positive blood culture from March to May 2002, even under an adequate dose of intravenous vancomycin (serum trough level of vancomycin = 9–24 µg/mL and serum peak level = 18–30 µg/mL) and rifampin (600 mg/day). An infected thrombus over the subclavian vein was detected by venous duplex and thought to be an unresolved focus. Linezolid (600 mg every 12 h) was given for 10 days (April 30–May 9, 2002) but discontinued because of progressive thrombocytopenia. Vancomycin and rifampin were resumed on May 10, and positive blood culture with MRSA was noted on May 14. Oliguric renal failure developed in the patient on May 21 followed by shock, and he died on May 23.

A 72-year-old man (patient B) with coronary artery disease and chronic renal insufficiency underwent coronary artery bypass grafting and aortic grafting for abdominal aortic aneurysm in December 1999. The postoperative course was complicated with second-degree atrioventricular block and progressive renal failure. He was implanted with a permanent pacemaker and started long-term hemodialysis in March 2000. In April 2000, catheter (double lumen for hemodialysis)-related MRSA bacteremia developed in the patient. Vancomycin (1 g/week) was administered and the catheter was changed, but 17 successive episodes of MRSA bacteremia recurred from May to July 2000, despite an adequate serum level of vancomycin (trough level = 13–21 µg/mL and peak level = 24–38 µg/mL). Transesophageal echocardio-